Affymetrix quarterly sales top $100m:
This article was originally published in Clinica
Microarray market leader Affymetrix said that its preliminary financial data for the fourth quarter of financial 2004 indicated product and product-related revenues will exceed $100m for the first time in its 12-year history. In 2003 the Santa Clara, California company went into the black for the first time, reporting a net income of $14.3m on sales of $301m, 93% of which were product and product-related.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.